F M Investments LLC Purchases Shares of 2,404 United Therapeutics Co. (NASDAQ:UTHR)

F M Investments LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 2,404 shares of the biotechnology company’s stock, valued at approximately $848,000.

Several other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC grew its position in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 30 shares during the period. Parallel Advisors LLC grew its position in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC increased its stake in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after purchasing an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its position in United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Up 0.8 %

Shares of NASDAQ UTHR opened at $281.16 on Friday. The stock has a market cap of $12.63 billion, a PE ratio of 12.35, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 12-month low of $230.39 and a 12-month high of $417.82. The company has a 50-day moving average of $323.22 and a 200 day moving average of $351.14.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the business earned $4.36 earnings per share. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $939,625.74. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 87,500 shares of company stock valued at $30,640,680 in the last three months. 11.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on UTHR shares. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.